Detalhe da pesquisa
1.
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
N Engl J Med
; 389(19): 1778-1789, 2023 Nov 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37870949
2.
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.
Jpn J Clin Oncol
; 53(1): 16-25, 2023 Jan 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36300304
3.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Lancet Oncol
; 16(5): 499-508, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25877855
4.
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
Oncologist
; 19(4): 350-1, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24674871
5.
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
Eur Urol
; 83(5): 432-440, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36868932
6.
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
Eur Urol Oncol
; 5(5): 553-563, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35288066
7.
Corrigendum to "Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score" [Eur. Urol. 83(5) (2024) 432-440].
Eur Urol
; 85(3): e96-e97, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38176992
8.
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set.
ESMO Open
; 3(3): e000347, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29713498
9.
Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
Eur J Cancer
; 78: 61-69, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28412590
10.
Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.
Cancer Chemother Pharmacol
; 80(3): 599-608, 2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28744667
11.
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 78(4): 727-33, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27507037
12.
Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.
Anticancer Res
; 35(7): 4003-7, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26124348
13.
Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al.
Eur J Cancer
; 92: 121-122, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29433790